Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib

Míreanna Comhchosúla

• Propensity score analysis of overall survival between first‐ and second‐generation EGFR‐TKIs using real‐world data
  le: Ito, Kentaro, et al.
  Foilsithe: (2020)
• Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo
  le: Kudo, Kenichiro, et al.
  Foilsithe: (2017)
• Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations
  le: Tanaka, Kentaro, et al.
  Foilsithe: (2017)
• Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer With and Without T790M Mutations
  le: Janjigian, Yelena Y., et al.
  Foilsithe: (2014)
• Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation
  le: Zhang, Shirong, et al.
  Foilsithe: (2015)